Experimental Alzheimer’s Drug Slows Biomarker Progression in Early Trial

A cholesterol-lowering CETP inhibitor shows early promise for Alzheimer’s patients carrying APOE4

Obicetrapib, an experimental CETP inhibitor already known for lowering LDL cholesterol and raising HDL cholesterol in cardiovascular disease, slowed progression of a key Alzheimer’s biomarker (p-tau217) over 12 months. The effect was most notable in APOE4 carriers, who are at highest risk for both cardiovascular disease and Alzheimer’s.

Study Details

The …